Patents by Inventor Nikki Thiele

Nikki Thiele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210221715
    Abstract: Metal-chelating compositions having the structure (1a) wherein: R1, R2, R3, and R4 are independently selected from the following groups: (i) hydrogen atom, (ii) hydrocarbon groups (R) containing 1-12 carbon atoms; (iii) halogen atoms; (iv) —P(R5)(?O)OH groups; (v) —C(?O)OH groups; (vi) —S(?O)2OH groups; and (vii) —OH groups, wherein R5 is selected from hydrocarbon groups (R) and —OH; R1 and R2 may optionally interconnect to form Ring A fused to the ring on which R1 and R2 are present; R3 and R4 may optionally interconnect to form Ring B fused to the ring on which R3 and R4 are present; wherein Ring A and Ring B are optionally and independently substituted with one or more of groups (ii)-(vii). Methods of using the above-described compositions for chelating metal ions having an atomic number of at least 56 (e.g., Ba or Ra) are also described.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 22, 2021
    Applicant: CORNELL UNIVERSITY
    Inventors: Justin WILSON, Nikki THIELE
  • Publication number: 20210085808
    Abstract: The present technology provides compounds as well as compositions including such compounds useful for the treatment of cancers where the compounds are represented by the following formula (I) or a pharmaceutically acceptable salt thereof, wherein M is an alpha-emitting radionuclide.
    Type: Application
    Filed: March 30, 2018
    Publication date: March 25, 2021
    Applicant: CORNELL UNIVERSITY
    Inventors: Justin WILSON, Nikki THIELE
  • Publication number: 20200157087
    Abstract: The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
    Type: Application
    Filed: November 20, 2019
    Publication date: May 21, 2020
    Applicant: Cornell University
    Inventors: John W. Babich, Justin Wilson, Nikki Thiele, James Kelly, Shashikanth Ponnala